Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$12.60 USD
+0.69 (5.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $12.63 +0.03 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.60 USD
+0.69 (5.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $12.63 +0.03 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?
by Zacks Equity Research
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UROGEN PHARMA (URGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -6.36% and 0.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of 7.14% and -10.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.
UroGen Pharma Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
5 Best Performing IPOs of 2017
by Zacks Equity Research
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.